Morgan Stanley Maintains Equal-Weight Rating for PTC Therapeutics: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Morgan Stanley has maintained its Equal-Weight rating for PTC Therapeutics (NASDAQ:PTCT) but lowered its price target from $50.00 to $47.00. PTC Therapeutics' shares are currently trading down 1.6% at $39.62 per share. A move to $47.00 would represent an 18.61% increase from the current share price.
July 11, 2023 | 5:01 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Morgan Stanley has maintained its Equal-Weight rating for PTC Therapeutics but lowered its price target. This could potentially impact the stock's performance in the short term.
The lowering of the price target by Morgan Stanley could potentially lead to a decrease in the stock price of PTC Therapeutics in the short term. Investors may perceive this as a lack of confidence in the company's future performance, which could lead to selling pressure.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100